| Cas No.: | 1116743-46-4 |
| Chemical Name: | 1-(6-((6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)thio)benzo[d]thiazol-2-yl)-3-(2-morpholinoethyl)urea |
| Synonyms: | SAR125844; SAR 125844; SAR-125844 |
| SMILES: | O=C(NCCN1CCOCC1)NC2=NC3=CC=C(SC4=NN=C5C=CC(C6=CC=C(F)C=C6)=NN54)C=C3S2 |
| Formula: | C25H23FN8O2S2 |
| M.Wt: | 550.63 |
| Purity: | >98% |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | SAR125844 is a potent, highly selective, reversible and ATP-competitive MET receptor tyrosine kinase (RTK) inhibitor for intravenous administration, with an IC50 of 4.2 nM. Shows inhibition of MET autophosphorylation in cell-based assays[1]. |
| Target: | IC50: 4.2 nM (MET RTK)[1]. |
| References: | [1]. Egile C, et al. The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer. Mol Cancer Ther. 2015 Feb;14(2):384-94. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|